Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NIH × Miransertib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

Specimen Handling 150 Cyclophosphamide 144 Magnetic Resonance Spectroscopy 130 Biopsy 106 Radiotherapy 100 Bevacizumab 99 Cisplatin 97 Carboplatin 89 Doxorubicin 80 Paclitaxel 78 Etoposide 75 Filgrastim 72 aldesleukin 69 Fluorouracil 68 Gemcitabine 65 Vincristine 64 Leucovorin 57 Docetaxel 52 fludarabine phosphate 51 Bortezomib 50 Rituximab 45 Oxaliplatin 44 Sorafenib 43 Cytarabine 43 Immunoglobulin G 40 Disulfides 40 sargramostim 39 Sirolimus 39 Prednisone 39 Methotrexate 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04316546 2026-03-11

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡